Protalea Bio develops therapeutic antibodies that target glycosphingolipid‑related inflammation to prevent age‑associated cancers and neurodegenerative diseases before they manifest. By leveraging insights from Gaucher disease and lysosomal biology, its first‑in‑class treatments aim to halt disease progression, extending healthy lifespan. The approach focuses on early intervention in pre‑disease states, offering a preventive strategy rather than reactive therapy.
Funding
Funding not disclosed
Founders
Product
Problem
Age‑related changes in glycosphingolipid metabolism cause low‑grade inflammation that increases the risk of certain cancers and neurodegenerative diseases, yet current therapies address these conditions only after they have manifested.
Solution
Protalea Bio is creating first‑in‑class therapeutic antibodies that neutralize glycosphingolipid‑driven inflammation before disease onset. By targeting the upstream inflammatory pathway linked to Gaucher disease and related lysosomal dysfunction, the antibodies aim to prevent the progression of age‑associated cancers such as myeloma and liver malignancies, as well as neuroinflammatory processes that contribute to neurodegeneration. The approach leverages a decade of research in lysosomal biology and sphingolipid metabolism to design antibodies that intervene at the pre‑disease stage, thereby extending healthy lifespan for at‑risk populations.
Target Audience
Primary customers are pharmaceutical partners and clinical research organizations developing preventive therapies for age‑related cancers and neurodegenerative disorders, as well as healthcare systems seeking to implement early‑intervention strategies for at‑risk populations.
Features
- Antibody candidates engineered to bind specific glycosphingolipid antigens implicated in chronic inflammation
- Mechanistic focus on lysosomal and sphingolipid pathways identified through Gaucher disease research
- Preclinical models demonstrating reduction of inflammation markers linked to cancer and neurodegeneration risk
- Platform designed for prophylactic administration in individuals with identified genetic or biomarker risk factors
- Potential for combination with existing screening programs to identify candidates for early intervention